NCT00356486 - Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

HIV Infections

Interventions

DRUG

Peginterferon alfa-2a, Ribavirin, epoetin-β

Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks

DRUG

Peginterferon alfa-2a + Ribavirin for 12 weeks

Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks

Trial Locations (12)

11009

Hospital Puerta del Mar, Cadiz

20012

Hospital de Donostia, San Sebastián

28007

Hospital Gregorio Marañón., Madrid

Hospital Ramón y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

28046

Hospital La Paz, Madrid

46014

Hospital General Universitario de Alicante, Alicante

08916

Hospital Germans Trias i Pujol, Badalona, Badalona

08221

Consorci Sanitari de Terrassa, Terrassa

08500

Hospital General de Vic, Vic

08003

Hospital del Mar, Barcelona

08036

Hospital Clínic i Provincial, Barcelona

All Listed Sponsors

collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

lead

Germans Trias i Pujol Hospital

OTHER